{"id":"NCT04005352","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)","officialTitle":"A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration (TALON)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-25","primaryCompletion":"2022-09-09","completion":"2022-09-09","firstPosted":"2019-07-02","resultsPosted":"2024-01-30","lastUpdate":"2024-10-09"},"enrollment":734,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Age-related Macular Degeneration"],"interventions":[{"type":"BIOLOGICAL","name":"Brolucizumab 6 mg","otherNames":["RTH258"]},{"type":"BIOLOGICAL","name":"Aflibercept 2 mg","otherNames":["EYLEA"]}],"arms":[{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL"},{"label":"Aflibercept 2 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.","primaryOutcome":{"measure":"Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye","timeFrame":"Up to Week 32","effectByArm":[{"arm":"Brolucizumab 6 mg","deltaMin":141,"sd":null},{"arm":"Aflibercept 2 mg","deltaMin":73,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":118,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Israel","Italy","Malaysia","Netherlands","Portugal","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1914"]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":366},"commonTop":["Neovascular age-related macular degeneration - Fellow Eye","Visual acuity reduced - Study Eye","Conjunctival haemorrhage - Study Eye","Hypertension","Eye pain - Study Eye"]}}